Search

Last month the world's leading pharmaceutical company received simultaneous FDA approval for two new therapies. Yet neither drug was invented by the company. Both were originally developed by small biotechs.

There is much more work to do to convince public opinion that bioscience is a force for good, says UK BioIndustry Association chairman Simon Best.

On 26 January, in London, Science|Business organised a roundtable of executives in the biotech industry to discuss the state of the market. The consensus: investor appetite for biotech companies is on the rise.

With high oil prices showing no sign of quitting, "cleantech" is the new darling VC investment sector. But, asks Mary Lisbeth D'Amico, is the market more froth than substance?

Ireland's fastest-growing companies hired even more aggressively than other top job-creating European companies during 2001-2004, according to a survey conducted by Entrepreneurs for Growth, a membership-based organisation representing 2,000 European firms.

The founding dean of INSEAD's Singapore campus is moving to the UK to head up the Judge Business School at Cambridge.

TU Delft ditched the usual model of outlicensing or seeking venture capital backing when it was looking to commercialise a novel wastewater treatment technology.

In the past five years the state of Saxony in the former East Germany has made great strides in creating a biosciences sector – outstripping progress made by some of its counterparts in the more prosperous west of the country.

Dental implant company Neoss Ltd raised £5 million in its third funding round, enabling it to further develop the technology and expand its sales and marketing operations.

A pre-designed biomanufacturing facility with advance planning permission is the latest carrot devised by the Industrial Development Authority (IDA) Ireland in its efforts to attract international biopharmaceutical manufacturing projects.

The European Commission is reviving a push for a common patent policy by asking for input of ideas from industry and stakeholders - a move that would renew a fierce debate that has spanned more than three decades.